These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31243887)

  • 21. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation.
    Shaked A; DesMarais MR; Kopetskie H; Feng S; Punch JD; Levitsky J; Reyes J; Klintmalm GB; Demetris AJ; Burrell BE; Priore A; Bridges ND; Sayre PH
    Am J Transplant; 2019 May; 19(5):1397-1409. PubMed ID: 30506630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kidney allograft failure in the steroid-free immunosuppression era: A matched case-control study.
    Alkadi MM; Kim J; Aull MJ; Schwartz JE; Lee JR; Watkins A; Lee JB; Dadhania DM; Seshan SV; Serur D; Kapur S; Suthanthiran M; Hartono C; Muthukumar T
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28921709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
    Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X
    Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medication adherence and rejection rates in older vs younger adult liver transplant recipients.
    Leven EA; Annunziato R; Helcer J; Lieber SR; Knight CS; Wlodarkiewicz C; Soriano RP; Florman SS; Schiano TD; Shemesh E
    Clin Transplant; 2017 Jun; 31(6):. PubMed ID: 28370346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posttransplant muscle mass measured by urinary creatinine excretion rate predicts long-term outcomes after liver transplantation.
    Stam SP; Osté MCJ; Eisenga MF; Blokzijl H; van den Berg AP; Bakker SJL; de Meijer VE
    Am J Transplant; 2019 Feb; 19(2):540-550. PubMed ID: 29745020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection.
    Terrault NA; Roland ME; Schiano T; Dove L; Wong MT; Poordad F; Ragni MV; Barin B; Simon D; Olthoff KM; Johnson L; Stosor V; Jayaweera D; Fung J; Sherman KE; Subramanian A; Millis JM; Slakey D; Berg CL; Carlson L; Ferrell L; Stablein DM; Odim J; Fox L; Stock PG;
    Liver Transpl; 2012 Jun; 18(6):716-26. PubMed ID: 22328294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
    Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
    Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study.
    TruneČka P; Klempnauer J; Bechstein WO; Pirenne J; Friman S; Zhao A; Isoniemi H; Rostaing L; Settmacher U; Mönch C; Brown M; Undre N; Tisone G;
    Am J Transplant; 2015 Jul; 15(7):1843-54. PubMed ID: 25707487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prednisone-free maintenance immunosuppression in obese kidney transplant recipients.
    Matas AJ; Vock DM
    Clin Transplant; 2019 Oct; 33(10):e13668. PubMed ID: 31310030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
    Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
    Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
    Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphocyte depletion and risk of acute rejection in renal transplant recipients at increased risk for delayed graft function.
    Ravindra KV; Sanoff S; Vikraman D; Zaaroura A; Nanavati A; Sudan D; Irish W
    Am J Transplant; 2019 Mar; 19(3):781-789. PubMed ID: 30171800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transplantation in foreign nationals: Lower rates of waitlist mortality and higher rates of lost to follow-up posttransplant.
    Ferrante ND; Goldberg DS
    Am J Transplant; 2018 Nov; 18(11):2663-2669. PubMed ID: 29981179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional status at listing predicts waitlist and posttransplant mortality in pediatric liver transplant candidates.
    Perito ER; Bucuvalas J; Lai JC
    Am J Transplant; 2019 May; 19(5):1388-1396. PubMed ID: 30506640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
    Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.
    Vondrak K; Parisi F; Dhawan A; Grenda R; Webb NJA; Marks SD; Debray D; Holt RCL; Lachaux A; Kelly D; Kazeem G; Undre N
    Clin Transplant; 2019 Oct; 33(10):e13698. PubMed ID: 31436896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond death and graft survival-Variation in outcomes after liver transplant. Results from the NSQIP transplant beta phase.
    Parekh JR; Greenstein S; Sudan DL; Grieco A; Cohen ME; Hall BL; Ko CY; Hirose R
    Am J Transplant; 2019 Jul; 19(7):2108-2115. PubMed ID: 30887634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
    Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
    Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kidney allograft function and histology in recipients dying with a functioning graft.
    Lorenz EC; El-Zoghby ZM; Amer H; Dean PG; Hathcock MA; Kremers WK; Stegall MD; Cosio FG
    Am J Transplant; 2014 Jul; 14(7):1612-8. PubMed ID: 24910299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.